MBL Wealth 13F: Adds $1.1M to Pfizer (PFE) Stake

MBL Wealth boosted its stake in Pfizer Inc. (PFE) by 188.7%, acquiring 39,628 more shares during the quarter to bring its total holding to 60,631 shares. The move was revealed in a Form 13F filing with the SEC on October 22, 2026. The total value of the investment reached about $1.73 million.

PFE Pfizer Inc.

$30.42 ▲ +27.07% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in MBL Wealth's Pfizer Position

Before this update, the fund held 21,003 shares of the healthcare company. Adding 39,628 shares resulted in a stake of 60,631 shares valued at $1,729,197.00. The 188.7% increase reflects a larger commitment to the drug manufacturer.

Other Institutional Activity in Pfizer

Other large holders also adjusted their positions in the drug maker during the period. Symphony Financial grew its holdings by 58,554 shares, ending with 98,868 shares worth about $2.83 million. Tectonic Advisors lifted its stake by 33,109 shares to 465,200 shares valued at about $13.27 million. Meanwhile, Quilter trimmed its position by 41,417 shares, leaving it with 621,511 shares worth about $17.73 million.

Pfizer Inc. Stock Up 0.6%

Pfizer shares recently traded around $30.03 as of October 24, 2026, down about 1.3% since the stock closed at $30.42 on October 22. The price sits below its 52-week high of $30.44 and above its 50-day moving average of $28.23.

Recent Earnings

Pfizer reported trailing-twelve-month revenue of $63.7 billion and basic earnings per share of $0.76. Investors are watching for the next earnings report scheduled for November 3, 2026.

Dividend

Pfizer distributes an annual dividend rate of $1.72 per share, which translates to a dividend yield of 5.65%.

Insider Buying and Selling at Pfizer Inc.

Company insiders executed several transactions ahead of the filing. On August 5, 2026, officer Jennifer B. Damico sold 3,278 shares, while director Ronald E. Blaylock bought 39,231 shares. CEO Albert Bourla purchased 38,000 shares on August 12, 2026.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. Guggenheim maintained a buy rating on August 7, 2026, while adjusting its target from $35.00 to $31.00. HSBC kept a hold rating on September 10, 2026, moving its target from $28.00 to $30.00.

About Pfizer

Pfizer Inc. is a New York-based healthcare company that discovers, develops, and distributes biopharmaceutical products globally. It operates through segments focused on biopharmaceuticals and related treatments, serving patients and medical providers worldwide.

Bottom Line

Institutional interest in Pfizer remains active as investors await the company's next earnings report on November 3, 2026. Future filings will show whether funds like MBL Wealth continue to expand their positions in the pharmaceutical giant.